Agonist News and Research

RSS

Teva reports 31% increase in non-GAAP net income for first-quarter 2010

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended March 31, 2010.

4 May 2010

FDA issues advisory on prostate cancer drugs

Gonadotropin-Releasing Hormone (GnRH) agonists, a class of medications primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing analysis of several studies by the U.S. Food and Drug Administration.

3 May 2010

Santen licenses Clinical Data's ATL313 agonist compound for development of ophthalmic treatments

Clinical Data, Inc., and Santen Pharmaceutical Co., Ltd., today announced that Santen has exercised its option to license Clinical Data's highly selective adenosine A2A agonist compound, ATL313, for the development of topical treatments for certain ophthalmic diseases, including glaucoma. ATL313, a promising late-stage preclinical compound, has shown significant pharmacological effects in vivo and has been nominated as a clinical candidate.

From Santen Pharmaceutical Co., Ltd. 3 May 2010

Manipulating physiology of "kissing bug" may help prevent transmission of Chagas' disease

It makes your skin crawl-a bug that crawls onto your lips while you sleep, drawn by the exhaled carbon dioxide, numbs your skin, bites, then gorges on your blood. And if that's not insult enough, it promptly defecates on the wound-and passes on a potentially deadly disease.

30 Apr 2010

Adolor's ENTEREG first-quarter net product sales increases to $5.3 million

Adolor Corporation today reported a net loss of $9.6 million, or $(0.21) per basic and diluted share, for the three months ended March 31, 2010, compared to a net loss of $13.2 million, or $(0.28) per basic and diluted share, for the three months ended March 31, 2009.

29 Apr 2010

Researchers receive $5.7M in funding to investigate new ways to treat uterine fibroids

As many as 75 percent of women have uterine fibroids (leiomyomas), and approximately one-third to one-half of those women become symptomatic at some point during their reproductive lives - experiencing irregular uterine bleeding, anemia, pelvic pain or recurrent pregnancy loss.

28 Apr 2010

Alair Bronchial Thermoplasty System receives FDA approval to treat asthma in adults

The U.S. Food and Drug Administration today approved the first medical device that uses radiofrequency energy to treat severe and persistent asthma in certain adults.

28 Apr 2010

Advair to remain favored fixed-dose LABA/ICS combination therapy through 2013 for asthma and COPD

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite increased competition from several emerging agents, GlaxoSmithKline's Advair will remain surveyed pulmonologists' and primary care physicians' (PCPs) favored fixed-dose long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combination inhaler through 2013 for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

27 Apr 2010

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the companies have submitted their reply to a complete response letter issued last month by the U.S. Food and Drug Administration (FDA) after review of the New Drug Application (NDA) submission for BYDUREON™ (exenatide for extended-release injectable suspension).

23 Apr 2010

Forest Laboratories' fourth-quarter net sales up 11.0% to $995.6M

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.07 in the fourth quarter of fiscal 2010.

21 Apr 2010

Study evaluates therapeutic effects of FXR and TGR5 agonist in PSC

Results of a study presented today at the International Liver Congress 2010 demonstrate that a dual FXR and TGR5 agonist decreases liver damage and modulates hepatic inflammation and fibrosis in a mouse model of primary sclerosing chlolangitis. In contrast, selective FXR or TGR5 agonists have no beneficial effect.

19 Apr 2010

CombinatoRx's synergistic drug combinations for cancer treatment to be highlighted at AACR 2010

CombinatoRx, Incorporated today announced that preclinical data on its discovery of novel synergistic drug combinations for the treatment of cancer will be highlighted at the 101st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC.

16 Apr 2010

Positive interim data from Idera Pharmaceuticals' Phase 1 trial of IMO-2125 TLR9 agonist presented at 45th EASL

Idera Pharmaceuticals, Inc. announced today that positive interim data from a Phase 1 clinical trial of IMO-2125, a Toll-like Receptor 9 (TLR9) agonist, in null responder patients with chronic hepatitis C virus (HCV) infection were presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL).

16 Apr 2010

Low levels of vitamin D associated with lower lung function in children with asthma

Low levels of vitamin D are associated with lower lung function and greater medication use in children with asthma, according to researchers at National Jewish Health. In a paper published online this week in the Journal of Allergy & Clinical Immunology, Daniel Searing, MD, and his colleagues also reported that vitamin D enhances the activity of corticosteroids, the most effective controller medication for asthma.

16 Apr 2010

Synergistic interactions of A2A Agonist and PDE Inhibitors as adjunctive therapy to GC for treating MM

“Glucocorticoids are a key component of combination therapy regimens in multiple myeloma and other hematological cancers. However, glucocorticoid use comes with substantial dose limiting toxicities. The ability to enhance glucocorticoid dependent effects while sparing associated toxicities may have important implications for the treatment of multiple myeloma and other B-cell malignancies”

15 Apr 2010

Aspirin can reduce acute migraine attacks

A single dose of 900-1000 mg aspirin can substantially reduce migraine headache pain within two hours, for more than half of people who take it. It also reduces any associated nausea, vomiting, and sensitivity to light or sound (photophobia or phonophobia).

15 Apr 2010

New muco-adhesive patch may help treat oral disorders

A newly developed time-released muco-adhesive patch for treating oral health conditions, including the widespread condition of dry mouth (xerostomia), has been shown to be more effective than a leading oral rinse, according to a newly-published study.

6 Apr 2010

Hamamatsu launches FDSS/uCELL imaging plate reader for kinetic cell-based assay development

Hamamatsu has announced the release of the FDSS/uCELL, an affordable new imaging plate reader for kinetic cell-based assay development, including GPCR and ion channel research. The uCELL ("micro cell") offers a cost-effective way for biotechnology companies, research institutes, and clinical research organizations to introduce the highly reliable and advanced Hamamatsu FDSS (Functional Drug Screening System) technology to their daily operations.

2 Apr 2010

Pramipexole ER uptake to be inhibited by availability of generic version

HealthLeaders-InterStudy and Fingertip Formulary find that the uptake of Boehringer Ingelheim's pramipexole ER, the once-daily formulation of its market leading dopamine agonist Mirapex that was approved earlier this month, will be inhibited by competition from generic pramipexole which became available earlier this year.

1 Apr 2010

Patients switching to Victoza experience further reductions in A1c and weight loss

Diabetes Care published online the results of the Novo Nordisk LEAD™ 6 extension study, which evaluated the efficacy and safety of switching from exenatide, which is taken twice a day, to once-daily Victoza®. Results show that when added to oral antidiabetes drugs, patients who switched from exenatide to Victoza experienced further reductions in A1c and weight loss.

31 Mar 2010

Agonist News and Research

Teva reports 31% increase in non-GAAP net income for first-quarter 2010

FDA issues advisory on prostate cancer drugs

Santen licenses Clinical Data's ATL313 agonist compound for development of ophthalmic treatments

Manipulating physiology of "kissing bug" may help prevent transmission of Chagas' disease

Adolor's ENTEREG first-quarter net product sales increases to $5.3 million

Researchers receive $5.7M in funding to investigate new ways to treat uterine fibroids

Alair Bronchial Thermoplasty System receives FDA approval to treat asthma in adults

Advair to remain favored fixed-dose LABA/ICS combination therapy through 2013 for asthma and COPD

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

Forest Laboratories' fourth-quarter net sales up 11.0% to $995.6M

Study evaluates therapeutic effects of FXR and TGR5 agonist in PSC

CombinatoRx's synergistic drug combinations for cancer treatment to be highlighted at AACR 2010

Positive interim data from Idera Pharmaceuticals' Phase 1 trial of IMO-2125 TLR9 agonist presented at 45th EASL

Low levels of vitamin D associated with lower lung function in children with asthma

Synergistic interactions of A2A Agonist and PDE Inhibitors as adjunctive therapy to GC for treating MM

Aspirin can reduce acute migraine attacks

New muco-adhesive patch may help treat oral disorders

Hamamatsu launches FDSS/uCELL imaging plate reader for kinetic cell-based assay development

Pramipexole ER uptake to be inhibited by availability of generic version

Patients switching to Victoza experience further reductions in A1c and weight loss

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Discover how SciY empowers scientists

Latest News